As one of the world's leading biology CROs, GenScript has established a comprehensive drug development platform to integrate antibody engineering and antibody production technologies. Our scientists, with extensive experience in antibody drug development, provide superior services such as single domain antibody generation, antibody humanization, affinity maturation and antibody sequencing.
The biopharmaceuticals market in the U.S. is expected to increase to $144 billion by 2016, with an annual growth rate of 11.2%. Monoclonal antibody (mAbs) drugs represent a primary sector of the biopharmaceuticals market. The specificity of mAbs has tremendous clinical value, making them highly effective therapeutic agents. Many large pharmaceutical companies are increasing their investment in mAb research after the success of drugs such as Remicade™ and Rituxan™.
|Antibody Sequencing||Antibody Humanization|
|Biomolecular Interaction Analysis||Affinity Maturation|
|Chimeric Antibody Generation||Antibody Library and Phage Display|
|Epitope Mapping||Camelid Single Domain Antibody|
|Hybridoma Stabilization||Anti-idiotype Monoclonal Antibody|
|Antigen Production||Antibody Transient Expression|
|Premium Hybridoma Development||Antibody Stable Cell Line|
|In Vitro Assay and Screening||Antibody Production|
|In Vivo Efficacy and Safety|